TY - JOUR
T1 - Adjuvant treatment with trastuzumab of patients with HER2-positive, T1a-bN0M0 breast tumors
T2 - a systematic review and meta-analysis
AU - Hassing, Christina M S
AU - Nielsen, Dorte Lisbet
AU - Knoop, Ann Søegaard
AU - Tvedskov, Tove Holst Filtenborg
AU - Kroman, Niels
AU - Lænkholm, Anne-Vibeke
AU - Juhl, Carsten Bogh
AU - Kümler, Iben
N1 - Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.
PY - 2023/2/26
Y1 - 2023/2/26
N2 - The benefit of adjuvant trastuzumab treatment in patients with HER2-positive breast tumors ≤10mm without lymph node involvement (T1abN0) is insufficiently investigated. The aim of this systematic review and meta-analysis was to examine if adjuvant trastuzumab improves the prognosis in these patients. Databases were searched to identify interventional and observational studies evaluating the effect of trastuzumab on breast cancer specific survival (BCSS), disease free survival (DFS), distant recurrence free survival (DRFS), overall survival (OS) or recurrence free survival (RFS). Twelve studies examining the effect of trastuzumab and nine control studies without trastuzumab were identified (n = 6,927). Median follow-up was 36-123 months. Significantly improved DFS (Hazard Ratio (HR) 0.14, p<0.0001) and OS (HR 0.17, p=0.011) were found for patients receiving trastuzumab and chemotherapy compared to no trastuzumab/chemotherapy based on four and two studies. The prognosis was good even for patients without trastuzumab treatment: 5-year DFS 88.3% and 5-year OS 95.9%.
AB - The benefit of adjuvant trastuzumab treatment in patients with HER2-positive breast tumors ≤10mm without lymph node involvement (T1abN0) is insufficiently investigated. The aim of this systematic review and meta-analysis was to examine if adjuvant trastuzumab improves the prognosis in these patients. Databases were searched to identify interventional and observational studies evaluating the effect of trastuzumab on breast cancer specific survival (BCSS), disease free survival (DFS), distant recurrence free survival (DRFS), overall survival (OS) or recurrence free survival (RFS). Twelve studies examining the effect of trastuzumab and nine control studies without trastuzumab were identified (n = 6,927). Median follow-up was 36-123 months. Significantly improved DFS (Hazard Ratio (HR) 0.14, p<0.0001) and OS (HR 0.17, p=0.011) were found for patients receiving trastuzumab and chemotherapy compared to no trastuzumab/chemotherapy based on four and two studies. The prognosis was good even for patients without trastuzumab treatment: 5-year DFS 88.3% and 5-year OS 95.9%.
U2 - 10.1016/j.critrevonc.2023.103952
DO - 10.1016/j.critrevonc.2023.103952
M3 - Review
C2 - 36854373
SN - 1040-8428
VL - 184
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
M1 - 103952
ER -